Synovial Sarcoma, X Breakpoint 7 (SSX7) Peptide
-
- Target See all SSX7 products
- SSX7 (Synovial Sarcoma, X Breakpoint 7 (SSX7))
- Peptide Type
- Synthetic
- Origin
- Mammalian
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
- Sequence
- IFPKIMPKKP AEEGNDSKGV PEASGSQNDG KHLCPPGKPS TSEKINKTSG
- Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of SSX7 antibody,
Alternative Names: SSX7 control peptide, SSX7 antibody Blocking Peptide, Anti-SSX7 Blocking Peptide, synovial sarcoma, X breakpoint 7 Blocking Peptide, SSX7, SSX-7, SSX 7, SSX-7 Blocking Peptide, SSX 7 Blocking Peptide
-
-
- Application Notes
- Optimal conditions should be determined by the investigator
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handling Advice
- Avoid repeated freeze/thaw cycles.
- Storage
- -20 °C
- Storage Comment
- Store at -20 °C long term.
-
- Target
- SSX7 (Synovial Sarcoma, X Breakpoint 7 (SSX7))
- Synonyms
- SSX family member 7 Peptide, SSX7 Peptide
- Background
- SSX7 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas.
- Molecular Weight
- 21 kDa
-